Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KTTA Pasithea Therapeutics Corp.

Closed 08-31 16:00:00 EDT

0.5740

+0.0140

+2.50%

盘后0.5890

+0.0150+2.61%

19:10 EDT

High0.5860	Low0.5500	Vol450.55K
Open0.5731	D1 Closing0.5600	Amplitude6.42%
Mkt Cap19.18M	Tradable Cap5.86M	Total Shares33.41M
T/O255.11K	T/O Rate4.42%	Tradable Shares10.20M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"KTTA","market":"US","secType":"STK","nameCN":"Pasithea Therapeutics Corp.","latestPrice":0.574,"timestamp":1788206400000,"preClose":0.56,"halted":0,"volume":450554,"hourTrading":{"tag":"盘后","latestPrice":0.589,"preClose":0.574,"latestTime":"19:10 EDT","volume":760,"amount":433.2802,"timestamp":1788217812634,"change":0.015,"changeRate":0.026132,"amplitude":0.041812},"delay":0,"changeRate":0.02499999999999982,"floatShares":10202000,"shares":33414448,"eps":-1.482,"marketStatus":"Closed","change":0.014,"latestTime":"08-31 16:00:00 EDT","open":0.5731,"high":0.58595,"low":0.55,"amount":255110.658387,"amplitude":0.064196,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.482,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"listingDate":1628654400000,"exchange":"NASDAQ","adjPreClose":0.56,"preHourTrading":{"tag":"盘前","latestPrice":0.5752,"preClose":0.56,"latestTime":"09:13 EDT","volume":5687,"amount":3339.3353125,"timestamp":1788182023757,"change":0.0152,"changeRate":0.027143,"amplitude":0.044286},"postHourTrading":{"tag":"盘后","latestPrice":0.589,"preClose":0.574,"latestTime":"19:10 EDT","volume":760,"amount":433.2802,"timestamp":1788217812634,"change":0.015,"changeRate":0.026132,"amplitude":0.041812},"volumeRatio":1.864078},"requestUrl":"/m/hq/s/KTTA/tweets","defaultTab":"tweets","newsList":[{"id":"2661900842","title":"Pasithea Therapeutics Receives Nasdaq Extension on Listing Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661900842","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661900842?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:29","pubTimestamp":1787347787,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp ( ($KTTA) ) has shared an update. Pasithea Therapeutics disclosed that on February 20, 2026, Nasdaq notified the company...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-receives-nasdaq-extension-on-listing-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pasithea-therapeutics-receives-nasdaq-extension-on-listing-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661290936","title":"Pasithea Therapeutics Wins NASDAQ Extension to Regain $1 Minimum Bid Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2661290936","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661290936?lang=en_us&edition=fundamental","pubTime":"2026-08-22 05:08","pubTimestamp":1787346530,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics wins Nasdaq extension to regain $1 minimum bid compliancePasithea Therapeutics received a Nasdaq notice of non-compliance with the $1 minimum bid price rule.Nasdaq granted a 180-","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4qN5dB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659512109","title":"Pasithea Therapeutics Corp Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659512109","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659512109?lang=en_us&edition=fundamental","pubTime":"2026-08-15 05:14","pubTimestamp":1786742066,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp reports results for the quarter ended June 30 - Earnings SummaryPasithea Therapeutics CorpKTTA.OQreported a quarterly adjusted loss of 16 cents per share for the quarter end","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B1MK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659812902","title":"Pasithea Net Loss Widens 41.9% to $5.27 Million in Q2 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2659812902","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659812902?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:39","pubTimestamp":1786739969,"startTime":"0","endTime":"0","summary":"Pasithea net loss widens 41.9% to $5.27 million in Q2 2026Pasithea Therapeutics posted a Q2 net loss of $5.27 million, widening 41.9% from a year earlier.Operating loss widened 49.9% to $5.71 million as research and development expense climbed 71.5% to $3.69 million.General and administrative costs increased 22% to $2.03 million, while other income rose to $439,430.For the first half, net loss widened 11.9% to $8.14 million as operating loss increased 41.4% to $10.59 million.Cash, cash equivalents and restricted cash fell about $9.5 million in the first half; it had about $45.7 million on hand at June 30.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL7tKJyP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658893583","title":"Pasithea Therapeutics Corp Expected to Post a Loss of 16 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658893583","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658893583?lang=en_us&edition=fundamental","pubTime":"2026-08-10 19:46","pubTimestamp":1786362368,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics Corp <KTTA.OQ> expected to post a loss of16cents a share - Earnings PreviewPasithea Therapeutics CorpKTTA.OQKTTA.Ois expected to  report resultson August 12 (estimated) for the p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260810:nL8N4470PA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657629401","title":"Pasithea Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2657629401","media":"Reuters","labels":["shareholding","conferences","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657629401?lang=en_us&edition=fundamental","pubTime":"2026-08-08 05:19","pubTimestamp":1786137577,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics announces annual shareholder meetingPasithea Therapeutics will hold its annual stockholders meeting in a virtual format on Sept. 9, 2026.Stockholders will vote on the election of two Class III director nominees, including Tiago Reis Marques and Lawrence Steinman.Meeting agenda also includes ratifying CBIZ CPAs as independent auditor for the fiscal year ending Dec. 31, 2026.Investors will also consider a reverse stock split, with the board authorized to set a ratio from 1-for-2 to 1-for-20.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL3sKvpc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655481210","title":"Pasithea Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655481210","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655481210?lang=en_us&edition=fundamental","pubTime":"2026-07-30 05:31","pubTimestamp":1785360707,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics announces annual shareholder meetingPasithea Therapeutics will hold its annual stockholder meeting virtually on Sept. 9, 2026.Stockholders will vote on the election of two Class ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL7Dd1h2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653725209","title":"Pasithea Therapeutics Posts Investor Presentation on Pas-004 MEK Inhibitor Program in NF1 and Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2653725209","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653725209?lang=en_us&edition=fundamental","pubTime":"2026-07-21 23:53","pubTimestamp":1784649216,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics posts investor presentation on PAS-004 MEK inhibitor program in NF1 and solid tumorsPasithea highlighted PAS-004, a next-generation macrocyclic MEK1/2 inhibitor, as its lead prog","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL5d3MQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653271935","title":"Pasithea Therapeutics Posts Press Release on Pas-004 Data Presentation at ESMO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2653271935","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653271935?lang=en_us&edition=fundamental","pubTime":"2026-07-21 19:03","pubTimestamp":1784631818,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics posts press release on PAS-004 data presentation at ESMO 2026Pasithea posted a new press release on PAS-004 ahead of an ESMO Congress 2026 poster on its Phase 1 dose-escalation s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL4DbvDv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTAW","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651113499","title":"Pasithea Publishes Investor Presentation on Pas-004 Macrocyclic MEK Inhibitor Program in NF1 and Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651113499","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651113499?lang=en_us&edition=fundamental","pubTime":"2026-07-16 05:38","pubTimestamp":1784151510,"startTime":"0","endTime":"0","summary":"Pasithea publishes investor presentation on PAS-004 macrocyclic MEK inhibitor program in NF1 and solid tumorsPasithea outlined clinical development plans for PAS-004, a macrocyclic MEK1/2 inhibitor ta","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL69F8my:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649998636","title":"Pasithea Therapeutics to Attend B. Riley Securities Mind, Muscle & Vision Summit","url":"https://stock-news.laohu8.com/highlight/detail?id=2649998636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649998636?lang=en_us&edition=fundamental","pubTime":"2026-07-08 19:06","pubTimestamp":1783508813,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics to attend B. Riley Securities Mind, Muscle & Vision SummitPasithea Therapeutics will attend B. Riley Securities’ Mind, Muscle & Vision Summit on July 16, 2026, in Boston.Manageme","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260708:nNDL9Dx4bV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649064975","title":"Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2649064975","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649064975?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:21","pubTimestamp":1783322486,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Pasithea Therapeutics Corp::*ANNOUNCES POSITIVE INTERIM PHASE 1 ADVANCED CANCER STUDY DATA DEMONSTRATING LONG-TERM SAFETY AND TOLERABILITY, AND DURABLE CLINICAL ACTIVITY IN MEK/BRA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD2YksQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647583845","title":"Pasithea Therapeutics announces updated data from PAS-004 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2647583845","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647583845?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:15","pubTimestamp":1782818144,"startTime":"0","endTime":"0","summary":"Pasithea Therapeutics (KTTA) announced updated interim safety and clinical activity data from its ongoing first-in-human trial evaluating PAS-004 i...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-announces-updated-data-from-pas-004-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/pasithea-therapeutics-announces-updated-data-from-pas-004-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647980530","title":"Pasithea Therapeutics Corp - Protocol Amendment Extends Dose Escalation up to 52mg for Pas-4","url":"https://stock-news.laohu8.com/highlight/detail?id=2647980530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647980530?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647653093","title":"Pasithea Therapeutics Corp - Pas-4 Shows Favorable Safety Profile with Only Grade 1 or 2 Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2647653093","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647653093?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530933","title":"Pasithea Therapeutics Corp - Initiates Pilot Food Effect Study for Pas-4 Pharmacokinetics","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530933","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530933?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647305735","title":"Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-term Safety and Tolerability, and Durable Clinical Activity in Mek/braf-pretreated Patients, Plus Protocol Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2647305735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647305735?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA3JB5CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530165","title":"Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530165","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530165?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:00","pubTimestamp":1782817200,"startTime":"0","endTime":"0","summary":"--Favorable Safety Profile Supports Long-Term Chronic Dosing: PAS-004 has been well-tolerated, with all treatment-related adverse events (TRAEs) being Grade 1 or 2, no observed cardiac or retinal trea","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/30/3319538/0/en/Pasithea-Therapeutics-Announces-Positive-Interim-Phase-1-Advanced-Cancer-Study-Data-Demonstrating-Long-Term-Safety-and-Tolerability-and-Durable-Clinical-Activity-in-MEK-BRAF-Pretre.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KTTA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645004895","title":"Major Investor Quietly Boosts Stake in Pasithea Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2645004895","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645004895?lang=en_us&edition=fundamental","pubTime":"2026-06-23 10:06","pubTimestamp":1782180392,"startTime":"0","endTime":"0","summary":"New insider activity at Pasithea Therapeutics Corp ( ($KTTA) ) has taken place on June 22, 2026. Significant shareholder Coastlands Capital LP has ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-pasithea-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/major-investor-quietly-boosts-stake-in-pasithea-therapeutics-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645073688","title":"Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2645073688","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645073688?lang=en_us&edition=fundamental","pubTime":"2026-06-22 22:31","pubTimestamp":1782138691,"startTime":"0","endTime":"0","summary":"Coastlands Capital bought 100,000 Pasithea Therapeutics common shares in an open-market purchase at $0.53 each.Holdings rose to 3,835,035 shares, held indirectly through Coastlands Capital.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL3Kw9fv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Coastlands Capital LP buys 100,000 Pasithea Therapeutics shares for $53,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KTTA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pasithea.com","stockEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.2444},{"period":"3month","weight":-0.2171},{"period":"6month","weight":-0.3648},{"period":"1year","weight":-0.3342},{"period":"ytd","weight":-0.5659}],"compareEarnings":[{"period":"1week","weight":0.0047},{"period":"1month","weight":0.0547},{"period":"3month","weight":0.017},{"period":"6month","weight":0.1215},{"period":"1year","weight":0.1856},{"period":"ytd","weight":0.1282}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.182441},{"month":2,"riseRate":0.4,"avgChangeRate":-0.152614},{"month":3,"riseRate":0.4,"avgChangeRate":-0.0152},{"month":4,"riseRate":0.2,"avgChangeRate":0.004803},{"month":5,"riseRate":0.4,"avgChangeRate":-0.176425},{"month":6,"riseRate":0.4,"avgChangeRate":-0.006229},{"month":7,"riseRate":0.8,"avgChangeRate":0.060824},{"month":8,"riseRate":0.6,"avgChangeRate":0.040581},{"month":9,"riseRate":0.5,"avgChangeRate":-0.003936},{"month":10,"riseRate":0.2,"avgChangeRate":-0.132455},{"month":11,"riseRate":0.4,"avgChangeRate":0.147256},{"month":12,"riseRate":0.4,"avgChangeRate":-0.165941}],"exchange":"NASDAQ","name":"Pasithea Therapeutics Corp.","nameEN":"Pasithea Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Pasithea Therapeutics Corp.,KTTA,Pasithea Therapeutics Corp.股票,Pasithea Therapeutics Corp.股票老虎,Pasithea Therapeutics Corp.股票老虎国际,Pasithea Therapeutics Corp.行情,Pasithea Therapeutics Corp.股票行情,Pasithea Therapeutics Corp.股价,Pasithea Therapeutics Corp.股市,Pasithea Therapeutics Corp.股票价格,Pasithea Therapeutics Corp.股票交易,Pasithea Therapeutics Corp.股票购买,Pasithea Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Pasithea Therapeutics Corp.(KTTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Pasithea Therapeutics Corp.(KTTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}